Summary Regionally administered vasopressors might increase tumour chemotherapy uptake by differentially constricting normal and tumour blood vessels, leading to a selective increase in blood flow to the tumour. In this study, we compared the effects of the vasopressors angiotensin 11, vasopressin and endothelin and the vasodilator calcitonin gene-related peptide (CGRP) by continuously measuring liver parenchymal and tumour blood flow during a 30-min regional vasoactive infusion in a rat HSN liver metastasis model. Vasopressin and angiotensin 11 produced a vasoconstriction that decreased despite continued infusion, while endothelin infusion led to prolonged vasoconstriction with a more gradual onset. CGRP infusion resulted in increased vessel conductance but a reduction in blood flow due to systemic hypotension. The tumour to normal flow ratio (TNR) was transiently increased during infusion of all pressors, but only endothelin produced sufficient change to result in a rise in average TNR throughout pressor infusion. Continuous liver and tumour blood flow measurement throughout vasoactive infusion demonstrated that the extent and the duration of blood flow change varied with the agents assessed. No vasoactive agent increased tumour blood flow, but endothelin had the most suitable vasoactive properties for enhancing tumour uptake of continuously infused chemotherapy.
Forty per cent of patients with large bowel cancer develop liver metastases (Allen-Mersh et al, 1991) . Most will be treated by systemic 5-fluorouracil (5-FU)/folinic acid chemotherapy, which produces complete or partial tumour responses in only 23% of patients (Advanced Colorectal Cancer Meta-analysis Project, 1993) . There is a steep dose-response relationship between fluorouracil concentration and tumour cell kill (Hrynuik et al, 1987) , and one reason for the limited response of liver metastases to chemotherapy is poor tumour drug penetration. Tumour fluorinated pyrimidine levels can be increased tenfold by regional compared with systemic chemotherapy administration (Ensminger et al, 1978) , resulting in a 40-50% partial response rate (Dworkin and Allen-Mersh, 1992 ) and significant survival benefit (AllenMersh et al, 1994) . However, attempts to further improve response by increasing regional chemotherapy dose have produced unacceptable hepatotoxicity (Kemeny et al, 1990) because of a greater first-pass drug extraction by normal liver parenchyma than by metastases (Ensminger et al, 1978) . Thus, a means of increasing tumour drug uptake without producing parenchymal toxicity is required.
As chemotherapy uptake is influenced by blood flow (Dworkin et al, 1996) , one solution may be to increase tumour and reduce liver parenchymal blood flow by vasoactive manipulation. Previous studies of this strategy have focused on enhancing the tumour-liver parenchymal blood flow ratio (TNR) at a single time point, with the aim of increasing tumour uptake of a bolus chemotherapy dose (Sasaki et al, 1985) . However, the best results for treatment of colorectal liver metastases involve prolonged fluorinated pyrimidine infusion (Dworkin and Allen-Mersh, 1992) , which would require continuous vasoactive infusion. Therefore, continuous blood flow measurement is needed for assessment of the effect of vasoactive agents used with continuous chemotherapy infusion. We have used laser Doppler flowmetry (Almond and Wheatley, 1992) to assess liver and tumour blood flow changes in response to a continuous 30-min regional infusion of various vasoactive agents in an animal liver metastasis model.
METHODS

Liver metastasis animal model
The Hooded Sarcoma-N (HSN) tumour has similar in vivo hypovascular flow characteristics to human colorectal metastases (Hemmingway et al, 1991) . It was originally induced chemically (Currie and Gage, 1973) and has since been maintained in cell culture with Dulbecco's modified Eagle medium (Sigma) enriched with 10% fetal calf serum. HSN cells were trypsinized, resuspended in saline at a concentration of 5 x 106 ml-' and stored on ice before in vivo injection. Adult male Chester Beatty Hooded CBH/cbi rats (weight 300-375 g) were anaesthetized by inhalation of a halothane-oxygen mixture, and a lower midline laparotomy was performed. A mesenteric vein was injected with 1 x 106 HSN cells using a 21G needle, after which pressure was applied for 1-2 min to prevent bleeding. Care was taken to prevent extravasation of the HSN cells, which may lead to growth of mesenteric tumour at the injection site. Tumours 4-10 mm in diameter, which developed within 21-27 days of injection, were studied. A polythene cannula (Portex, 0.4 x 0.8 mm) was inserted into the right carotid artery and the intra-arterial blood pressure was measured continuously using a commercial pressure transducer (Fumess; FC0l 1). The results were recorded on a personal computer using Metrabyte (DAS8-PG) signal-processing hardware.
Vasoactive agents and doses
The selection of vasoactive dose was based on pilot studies whose aim was to achieve a measurable blood flow change while keeping the mean systemic blood pressure to within 0.75-1.25 of baseline. The vasoactive agents assessed and the doses administered were: the vasoconstrictors vasopressin (0.5 gg min-'), angiotensin II (4 gg kg-' min-') and endothelin I (0.05 gg min-') and the vasodilator calcitonin gene-related peptide (CGRP) (0.5 ,ig min-').
Experimental procedure
Three to four weeks after mesenteric vein tumour cell injection, animals were reanaesthetized and an upper midline laparotomy was performed. A fine haemostat was placed on the lower aspect of the first part of the duodenum, which was retracted downwards to expose the lesser omentum. The gastroduodenal artery, which leads into the common hepatic artery, was dissected free with British Journal of Cancer (1997) 76(9) (Grega and Adamski, 1987) , and clinical studies have reported a diminution of vasopressin-induced vasoconstriction during prolonged continuous regional infusion to control upper gastrointestinal haemorrhage (Conn, 1973) . We have suggested (Dworkin et al, 1995 ) that loss of vasopressin-induced vasoconstriction may be related to local nitric oxide release, as it can be prevented or reversed by the nitric oxide inhibitor L-nitro-arginine methyl ester. Endothelin-induced vasoconstriction was of slower (Figures 3 and 5 ) than with angiotensin II or vasopressin. This is in keeping with previous studies (Withrington et al, 1989) of the effect of endothelin in the liver and suggests that endothelin-induced vasoconstriction is differently mediated to that of angiotensin II or vasopressin. In order to increase tumour blood flow by vasoactive administration, there should be a differential response by normal and tumour circulations to the administered agent. This differential response could arise from a lack of smooth muscle (Krylova, 1969) or nerves (Mattson et al, 1977) within intratumoral vessels. Failure of intratumoral vasoconstriction to an infused vasoconstricting agent might thus lead to preferential blood flow through the tumour as the resistance in adjacent normal vessels rises. Neither the vasopressors nor the dilator (CGRP) that we studied increased intratumoral blood flow. The pressors induced a similar but less marked pressor effect of the same duration in tumour compared with normal liver parenchyma ( Figure 5 ). Some previous studies have suggested an increase in absolute tumour blood flow (Ackerman et al, 1988; Hemmingway et al, 1992) , while others (Mattsson and Peterson, 1988) Vasoactive infusion and tumour blood flow 1209 vasoactive agents in the same way as normal circulation. Possible explanations for our findings are that the pressor effect on normal parenchymal vessels supplying the tumour was sufficient to reduce tumour flow or that some intratumoral vessels were normal vessels that had been surrounded by local tumour growth but had retained nerves and smooth muscle capable of a pressor response. Decreased tumour blood flow could be associated with a chemotherapy advantage if the TNR was increased, thereby allowing administration of a higher chemotherapy dose with less blood flow and drug toxicity to normal tissues. TNR increase has been shown to enhance the tumour uptake of small tracer molecules (Hemmingway et al, 1991) and the cytotoxic effect (Suzuki et al, 1981; Bloom et al, 1987) . However, previous studies suggesting that vasoactive agents increase the TNR have measured blood flow with intermittent measuring techniques; these did not reveal either blood flow variations throughout vasoactive infusion (Burton, 1987; Carter et al, 1992) or the extent and direction of hepatic parenchymal and tumour blood flow change (Hafstrom et al, 1980; Burton et al, 1985) . All the pressors tested in our study (but not the dilator CGRP) produced a significant maximal increase in the TNR because of a relatively larger pressor effect in liver parenchyma than in tumour ( Figure 5 ).
We have previously suggested (Dworkin et al, 1996 ) that a significant but transient angiotensin Il-induced TNR increase achieved less chemotherapy advantage during continuous regional fluorouracil infusion than would be predicted by a TNR increase sustained throughout fluorouracil infusion. Assessment of the effects of continuous vasopressor infusion on both tumour-normal blood flow ratio and normal tissue blood flow over the days to weeks involved in clinical regional infusion chemotherapy would be difficult with the methods used in this study. However, the continuous flux measurements over a 30-min vasoactive infusion period in the present study did reveal that, although endothelin I produced the most sustained pressor effect with the only significant increase in average TNR of the agents tested ( Figure 5 ), this TNR effect was not sustained throughout the 30-min infusion (Figures 3 and 5 ). In addition, although the maximal effect in our study was to double the TNR, the average effect over the infusion period was less (roughly a 30% increase). While a regional endothelin-induced increase in tumour fluorouracil uptake of this order might increase response (Hrynuik et al, 1987) , it might also be limited by the hypertensive or cardiac effects of endothelin infusion. Although a clinical study would be needed to determine whether such an approach offered a therapeutic advantage at endothelin dose levels that did not damage normal tissues, the results from the present animal model study suggest that increases in tumour chemotherapy uptake sufficient to have an important impact on tumour response or survival are unlikely to be achieved. One reason for the limited effect of vasoactive blood flow manipulation on tumour blood flow and chemotherapy uptake may be the absence of vessels within the tumour for blood to be selectively shunted into (Burke et al, 1994) .
We conclude that the blood flow response to vasoactive infusion in this model of colorectal liver metastases varied with the agent tested. Although no agent increased tumour blood flow, maximal tumour to liver blood flow ratios were increased by vasoconstrictors. Only endothelin I produced a significant average TNR increase, but no agent significantly increased TNR throughout infusion.
